EFFECTS OF METABOLISM ON MESENCHYMAL STEM CELL-DERIVED EXTRACELLULAR VESICLES by Lee, Rachel
ABSTRACT 
 








Associate Professor Steven M. Jay, 
Fischell Department of Bioengineering 
 
Mesenchymal stem cells (MSCs) are under investigation for a wide variety of therapeutic 
applications. It has been determined that paracrine secretions are responsible for a 
significant portion of MSC bioactivity. Among these secretions, extracellular vesicles 
(EVs) have been discovered to have therapeutic potential. EVs have many applications, 
such as reduction of myocardial injury, wound repair, and promotion of angiogenesis. A 
recent spark in MSC- derived EV interest stems from the potential advantages they have 
over MSC transplantation. EVs are considered more stable, have a well-defined clearance 
pathway in vivo, and pose less safety risks due to their inability to differentiate. There is 
increasing interest in MSC-derived EVs and their potential clinical application, however, 
there are many barriers to realistic, widespread EV-based therapy. One of the more 
prevalent issues is a lack of knowledge behind the impact of various cell culture 
parameters, which have been shown to affect both MSCs and the EVs they produce. 
Specifically, evidence shows that cell culture conditions impact metabolic pathways, 
which provide important signals that contribute to MSC behavior and function. However, 
there have been no specific studies on the potential impact of MSC metabolism on EVs. 
My overarching hypothesis is that MSC EV production and function are dependent on the 
metabolic state of the parent MSCs. To test this hypothesis, two key metabolic pathways, 
glycolysis and oxidative phosphorylation, were inhibited to examine their effects on EV 
production. Metabolic effects on MSC EV bioactivity were also assessed using gap 
closure assays. Experiments were performed in both 2D and spheroid culture to assess 
continuity of results between platforms. In 2D culture, metabolic pathway inhibition did 
not impact MSC EV production capacity but did decrease EV bioactivity. In microcavity-
well culture plates, metabolic pathway inhibition decreased both MSC EV production 
capacity and EV bioactivity. These results indicate it is very likely that metabolism plays 
a mechanistic role in MSC EV production and bioactivity. Further studies are required to 
conclusively determine if metabolism impacts MSC EV production capacity, and they are 
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Chapter 1: Introduction 
 
1.1 Motivation  
Mesenchymal stem cells (MSCs) are under investigation for a wide variety of 
therapeutic applications as evidenced by hundreds of current clinical trials. Recently, a 
consensus has merged suggesting that paracrine secretions are responsible for a 
significant portion of MSC bioactivity.1 Among these secretions, which include 
chemokines and cytokines,2 extracellular vesicles (EVs) have more recently been 
discovered to have therapeutic potential. EVs are bioactive components secreted by 
MSCs,3 and they have been shown to have many applications, such as reduction of 
myocardial injury,4 wound repair, promotion of angiogenesis,5 and so on. In addition, the 
therapeutic use of MSC EVs has potential advantages over MSC transplantation. EVs are 
considered more stable than MSCs, while also having a well-defined clearance pathway 
in vivo. EVs also pose less safety risks because of their inability to differentiate or divide. 
Because of these factors, there is increasing interest in MSC-derived EVs and their 
potential clinical application.  
Despite the potential of EVs, there are many barriers to realistic, widespread EV-
based therapy development and use. One of the more prevalent issues is the lack of an 
established, standardized, and scalable biomanufacturing process. Currently, the common 
cell culture parameters used for EV biomanufacturing follow conventional methods, 
which were designed prior to the knowledge of EVs. It would be hugely beneficial to 
tailor cell culture toward optimal EV production conditions, which would enable higher 
yield and greater manufacturing efficiency. However, this is not currently possible due to 
lack of knowledge behind the cell culture parameters and mechanistic factors that drive 
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MSC EV production. To make therapeutic EV use a reality, we must better understand 
EVs and the factors that drive their production. 
1.2 Mesenchymal Stem Cells 
 Stem cells have various abilities such as self-renewal, capacity to differentiate 
into various lineages, and proliferation potential. There are two main types of pluripotent 
stem cells: embryonic (ESCs) and induced-pluripotent stem cells (iPSCs). ESCs are 
pluripotent stem cells isolated from the inner cell mass of human or mouse fibroblasts, 
and they have the potential to differentiate into three germ lines.15 ESCs originated prior 
to iPSCs and generated a lot of interest due to their vast therapeutic potential, but they 
have restrictions use due to ethical conflicts. This leads to the generation and use of 
iPSCs. iPSCs are produced from human fibroblasts through the overexpression of the 
transcription factors Oct4/3 (octamer binding transcription factor 4/3), Sox2 (sex 
determining region Y), Klf4 (kruppel-like factor 4), and c-Myc (Avian Myelocytomatosis 
virus oncogene cellular homologue),16 and, at the cellular level, they are almost 
completely like ESCs in terms of function. iPSCs avoid the ethical dilemma present with 
ESC use but may lack in function due to less genomic stability.  
 Stem cells, as stated, can differentiate into many lineages and have therapeutic 
potential. Specifically, MSCs, which can be produced from either ESCs or iPSCs, have 
been of recent interest due to their regenerative abilities. For instance, MSCs have been 
shown to facilitate the recovery of tissue injury in organs such as the heart, liver, and 
pancreas.17 MSCs are multipotent stromal cells, likely originating from the mesoderm, 
with the ability to differentiate into specialized cell lines such as osteoblasts and 
chondrocytes. A significant portion of MSC bioactivity stems from the cell’s paracrine 
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secretions, which are thought to be a major source of tissue repair. This mode of healing 
can enhance cell viability and proliferation, reduce apoptosis, and regulate immune 
response. Among these paracrine secretions are growth factors, hormones, cytokines, and 
extracellular vesicles.41 MSCs are self-renewable, easily accessible, and able to be 
expanded culturally in vitro.18 It is important to note that MSCs have high genomic 
stability and face very few ethical conflicts, making them good candidates for clinical 
translation and application. 
1.3 Mesenchymal Stem Cell Metabolism Effects 
 Many different mechanisms contribute to the self-renewal and differentiation 
potency of MSCs. Current evidence has demonstrated that, in addition to growth factors 
and extracellular matrix, metabolic pathways provide important signals that contribute to 
the optimization of MSC behavior and function.19 It has been shown that metabolic 
profile distinguishes the differentiated and undifferentiated state, with a changing 
mitochondrial morphology. There is a shift between glycolysis and oxidative 
phosphorylation that is linked to the cell’s pluripotent state20 (Figure 1). Glycolysis 
utilizes glucose to produce pyruvate and adenosine triphosphate (ATP), and oxidative 
phosphorylation functions under the TCA cycle. Pyruvate enters the TCA cycle initiating 
oxidative phosphorylation, which produces a higher ATP yield than glycolysis.21  
 4 
 
Figure 1. Metabolic pathways may provide crucial signals that contribute to the 
direction of pluripotency and self-renewal of stem cells. Glucose and oxidative 
phosphorylation have been shown to play a role in this process. Image adapted from 
Hu et al. 2015.24  
 
In undifferentiated MSCs, mitochondrial activity is low and glycolytic activity is high.22 
During the early stages of differentiation, MSC fate is directed through the 
downregulation of genes relating to pluripotency, upregulation of terminal-specific genes, 
and alteration of relevant metabolic enzymes.23 This information shows that metabolism 
is likely to play a role in MSC self-renewal, differentiation, and overall function. 
1.4 Extracellular Vesicles 
 All cells are capable of secreting different types of membrane vesicles, known as 
EVs. This process was conserved throughout evolution, and it occurs in bacteria, plants, 
and humans.6 The secretion of EVs was initially thought to be a means of eliminating 
waste, but it is now known that EVs have the capacity to exchange components between 
cells. Components exchanged vary from nucleic acids, lipids, proteins, and much more. 
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EVs are also able to act as signaling vehicles in homeostatic processes or pathological 
development.7  
 The term EVs is a blanketed description for the secreted materials, but the 
membrane vesicles produced are not that straightforward. The population is highly 
heterogeneous (Figure 2), with each different vesicle having its own characterization, 
function, and array of properties. This discovery allows for EVs to be classified into two 
types: exosomes and microvesicles.8  
 
Figure 2. Extracellular vesicles encompass a heterogeneous population produced by 
the cell. The different vesicles have varying origins, sizes, and morphology. This 
allowed for two classes of EVs to be identified. Image adapted from Niel et al. 2018.8 
 
 Exosomes are intraluminal vesicles (ILVs) formed through the inward budding of 
the membrane of multivesicular endosomes (MVEs) then release when there is fusion 
between MVEs and the plasma membrane (Figure 3). Their average diameter is reported 
to range from 50 to 150 nm. Exosomes are secreted from a variety of cell types, such as B 
lymphocytes9 and dendritic cells,10 and they have been shown to have potential 
involvement in immune regulation and intracellular communication.11 Microvesicles are 
subcellular materials generated by the outward budding of the plasma membrane and 
release to the extracellular space12 (Figure 3). They are known for their involvement with 
blood coagulation13 but also have a role in cell-cell communication in many cell types, 
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such as oncosomes.14 It is important to note the understanding of these processes is still 
questionable as EV biogenesis pathways may differ across cell types. Also, EV 
characterization is constantly changing and evolving as more knowledge is gained on the 
topic.  
 
Figure 3. Extracellular vesicles form in two ways. First, they are formed through 
budding within the lumen of MVEs. MVEs then fuse with the plasma membrane to 
release the ILVs called exosomes. Second, there is outward budding of the plasma 
membrane, which leads to the formation of microvesicles. Image adapted from Niel 
et al. 2018.8 
 
Mechanistic details of EV biogenesis have only recently been specified. 
Compared to microvesicles, mechanisms of exosome biogenesis are well understood. 
This allows them to be more easily manipulated and studied for therapeutic potential. 
Aside from exosomes and microvesicles, many EVs do not support therapeutic interests, 
such as shedding vesicles and apoptotic bodies. For these reasons, exosomes are of most 
interest and are often used in clinical studies and applications over other EVs.  
Although some EV biogenesis is well-defined, the mechanisms contributing to the 
efficiency of their release is still vague. When culturing MSCs for EV production, there is 
no optimal cell culture standard currently in place. This is mainly due to lack of 
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knowledge surrounding the specific mechanisms and cell culture parameters that 
contribute to MSC processes. For example, initial seeding density is a parameter of recent 
interest because it has been shown to effect MSC behavior, including EV production 
abilities. Studies have shown that when using a lower MSC seeding density (1E2 
cells/cm2), there is higher EV production.25 This behavior is not limited to MSCs. Human 
dermal microvascular endothelial cells (HDMECs), human embryonic kidney 293T 
(HEK) cells, and human umbilical vein endothelial cells (HUVECs) have also followed 
the trend of lower seeding density leading to greater EV production.25 Although there is a 
clear relationship between seeding density and MSC EV production, the mechanisms 
behind this are not currently understood. It is hypothesized that MSC metabolism is the 
cause of this trend, as studies have shown lower seeding densities are associated with 
increased metabolic rates in MSCs.27 Metabolism may be the mechanism behind many 
MSC behaviors, particularly pertaining to EV production and function. However, there is 
currently no literature confirming this. This lack of understanding prevents the 
optimization of MSCs in culture for EV biomanufacturing purposes, which is crucial for 
the potential production and clinical translation of EVs. 
1.5 Three-Dimensional Cell Culture 
 Two-dimensional (2D) cell culture has been normal practice for many years. 
However, three-dimensional (3D) culture is growing in popularity, as it allows a realistic 
microenvironment for the cells to grow. 3D cultures allow cells to grow in all directions, 
surround one another, and simulate in vivo conditions. The addition of a dimension 
creates more realistic spatial organization and physical constraints, which can affect both 
intracellular and extracellular signaling.38 Many groups have found that cells cultured in a 
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3D environment differ in morphology and physiology than those cultured in a 2D 
environment.33,34 Because of the in vivo like microenvironment, 3D culture provides 
more physiologically accurate and predictive cell behavior and data than that of 2D 
culture, which has been shown in various studies.35,36  
3D culture plates and scaffolds can mimic the extracellular matrix of 3D tissues 
and have controlled pore size and interconnectivity, making the environment more 
realistic.28 For the current development of 3D culture plates, the hanging drop method is 
the most common in manufacturing. This method uses spontaneous aggregation of cells 
on a drop of media and gravity to create 3D spheroids.29 However, this method is labor 
intensive and not realistically scalable, so other 3D cell culture methods are being 
explored. Microwell-containing well plates have been shown to be cost-effective, high 
throughput, and flexible in terms of size. Multiple groups have created sufficient 
microwells on culture plates and have found success using them for 3D culture.30,31 For 
example, 3D spheroids of MSCs have been successfully formed using a microwell-
containing culture plate as well. MSCs aggregated and formed spheroids in 24 hours; 
they maintained this morphology at 48 hours (Figure 4).32  
 
Figure 4. Mesenchymal stem cells form spheroids in a 3-dimensional microwell 
culture plate. At initial seeding, the cells sat at the bottom of the microwell in a 
monolayer. After 24 hours, the cells migrated to form a spheroid. This shape was 




Mesenchymal stem cells cultured in a 3D space have been studied by various 
groups, and this culture medium has been shown to have both effects on cell behavior and 
benefits. Compared to 2D culture, 3D culture conditions promote MSC self-renewal, 
differentiation, and upregulation of paracrine signaling.39 Ong SM, et al. demonstrated 
this when culturing MSCs three-dimensionally using a microfluidic system consisting of 
polymeric linkers and micro-fabricated pillar arrays. They were able to achieve total cell 
viability and 3D morphology using this culture method. Interestingly, they also saw 
improved cell functionality over those in 2D culture, and the MSCs exhibited the 
capability to differentiate.37 In addition to improved cell behavior and functionality, 3D-
cultured MSCs have improved therapeutic potential. It is thought MSC spheroids have 
increased survival after transplantation due to the enhanced angiogenic and anti-
inflammatory properties that come with the 3D culture approach, as well as increased 
stemness.40 The 3D culture of MSCs has a multitude of effects, as evidenced, but there is 
very little literature examining its impact on MSC EV production and behavior. The 
microenvironment of MSC culture is incredibly variable based on the purpose of culture, 
whether it be for small-scale culture and study or large-scale production and 
manufacturing. The likelihood of variations in MSC culture technique is high when the 
potential for a scalable culture format is considered. Therefore, it is important to 
understand the differences between MSC and MSC spheroid-produced EVs. For MSC 
EV therapeutic translation and use to become a reality, there must be a greater awareness 




1.6 Objectives  
 Metabolism affects various aspects of MSC activity and behavior, such as 
pluripotency and self-renewal. However, there is no literature examining the relationship 
between metabolism and MSC EVs. My overarching hypothesis is that metabolism plays 
a role in MSC EV production and bioactivity. I will examine this relationship by focusing 
on two key metabolic pathways, glycolysis and oxidative phosphorylation (OXPHOS), as 
these have been shown to impact MSC function and behavior.24 These pathways will be 
inhibited in MSCs, and the effects of this in EVs will be observed. Previous studies have 
shown that MSC proliferation increases when glycolysis is favored over oxidative 
phosphorylation.22 Therefore, we also hypothesize one pathway will have more of an 
impact on MSCs than the other, namely, glycolysis inhibition will more greatly affect 
EVs than OXPHOS inhibition. 
 To assess the effects of glycolysis and OXPHOS, I will inhibit these pathways 
chemically in vitro. MSC EV production capacity will be assessed using nanoparticle 
tracking analysis (NTA). EV bioactivity will be evaluated using a gap closure assay. 
Experiments will be performed in both 2D and spheroid culture to determine the 








Chapter 2: Materials and Methods 
 
2.1 Two-Dimensional Cell Culture 
Bone marrow derived MSCs were obtained from ATTC (PCS-500-012). Tissue 
culture polystyrene flasks were used. Cells were cultured in Dulbecco’s Modification of 
Eagles Medium (DMEM) with 10% fetal bovine serum (FBS), 1% Penn Strep (P/S), and 
1% non-essential amino acids (NEAA) added. The passage number used for experiments 
was 3 and 4, as it is shown that bioactivity does not vary between these passage 
numbers.25 When preparing for EV collection, EV-Depleted medium was used. Here, 
FBS was EV-Depleted by ultracentrifugation for 16 hours, then added to DMEM along 
with 1% P/S and 1% NEAA. This is referred to as “EV-Depleted medium.” 
Human umbilical vein endothelial cells (HUVECs) were obtained from 
PromoCell (C-12203). Tissue culture polystyrene flasks were coated with 0.1% gelatin at 
37oC for 1 hour. Once the flask was coated, the HUVECs, at passage number 3, were 
seeded. Cells were cultured using the Endothelial Cell Growth Medium GM MV 2 kit 
(PromoCell: C-39221), where all supplements added are provided and amounts are 
specified.  
2.2 Microcavity-Well Plate Cell Culture 
 Bone marrow derived MSCs were obtained from ATTC (PCS-500-012). MSCs 
were cultured in Corning Prototype Ultra Low Attachment (ULA) microcavity 6-well 
plate inserts. Cells were cultured in DMEM with 10% FBS, 1% P/S, and 1% NEAA. All 
MSCs used for spheroid formation were at passage number 4.  
To obtain spheroid formation, 500 MSCs were seeded in each microcavity (Figure 
5a). Because the culture flasks and well plate-inserts were ULA, extreme care was taken 
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during handling prevent spheroid detachment and loss. The angle of the vessel during 
media collection and exchange was kept to a minimum (~10o), and all actions were 
gentle. The timeline for MSC seeding and media collection and replacement can be seen 




Figure 5. Timeline used during microcavity-well MSC culture. MSCs were seeded, 
then allowed to incubate, undisturbed for 3 days to allow spheroid formation. On 
day 3, the medium is changed to EV-depleted medium. After 24 hours, the medium 
is collected for EV isolation and replaced with EV-depleted medium. This process 










2.3 Metabolic Pathway Inhibition 
 During pathway inhibition, MSCs were cultured in Glucose-Free DMEM 
obtained from Sigma-Aldrich (D5030-10X1L) in the form of a powder. The powder was 
resuspended in one liter of deionized water, and 3.7 grams of Sodium Bicarbonate 
(NaHCO3) was added for each liter of media. The solution was then filtered for sterility. 
Prior to use in culture, 10% EV-Depleted FBS (obtained via 16 hours ultracentrifugation 
of FBS), 1% P/S, and 1% NEAA were added to the media. This formulation was used for 
all experiments where metabolism was inhibited.    
Two metabolic pathways of MSCs were inhibited: glycolysis and oxidative 
phosphorylation (OXPHOS). Glycolysis was inhibited using 2-Deoxy-D-Glucose 
obtained from TCI Chemicals (D0051-1G). Deionized water was used for resuspension. 
OXPHOS was inhibited using Antimycin-A obtained from BioVision (2247-50). 95% 
Ethanol was used for resuspension.  
 24 hours prior to EV isolation, MSC culture medium was changed with Glucose-
Free, EV-Depleted DMEM with either 5mM 2-Deoxy-D-Glucose or 1!M Antimycin-A 
added. These concentrations were chosen based on preliminary results, which can be 
found in Chapter 3. MSCs incubated at 37oC, 5% CO2 for 24 hours, when medium was 
collected for EV isolation. 
2.4 EV Collection 
For the 2D EV production capacity experiments, MSCs were seeded at 
100cells/cm2 into T-25 tissue culture flasks using EV-rich medium. 24 hours later, the 
medium was aspirated and disposed. MSCs were washed twice with 1X PBS to ensure 
complete removal of EVs from the previous medium. 5mL of EV-Depleted medium was 
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then added. When either metabolic pathway was inhibited, 5mL of Glucose-Free, EV-
Depleted medium was added with either 5mM 2-Deoxy-D-Glucose or 1!M Antimycin-A 
included. After 24 hours, the medium was collected for EV isolation. The flasks were 
then trypsinized and cells were counted to develop an EV/cell measure. 4mL of trypsin 
was added to completely cover all cells, and the flasks were incubated for 5 minutes at 
37oC. Cells were collected and counted using a Hemocytometer.  
For the MSC spheroid EV production capacity experiments, MSCs were seeded 
into microcavity 6-well plate inserts at 500 cells per microcavity. MSCs incubated at 
37oC, 5% CO2 for 48 hours to allow for spheroid formation. Once spheroids formed, 
MSCs were washed twice with 1X PBS and 2mL of EV-Depleted medium was added to 
each well. Like in the 2D experiment, Glucose-Free, EV-Depleted medium with either 
5mM 2-Deoxy-D-Glucose or 1!M Antimycin-A was used for metabolic pathway 
inhibition. After 24 hours, the medium was collected for EV isolation. The well plates 
were trypsinized to determine cell viability and count for an EV/spheroid measure. 1mL 
of trypsin was added to each well, and the plates were incubated for 5 minutes at 37oC. 
Cells were collected and counted using a Hemocytometer. 
 For 2D EV bioactivity experiments, MSCs were seeded into a T-175 tissue 
culture flasks with EV-rich medium for a cell count of 250,000. 24 hours later, the 
medium was aspirated, cells were washed twice with 1X PBS, and 25mL of EV-Depleted 
medium was added. When a metabolic pathway was inhibited, 25mL of Glucose-Free, 
EV-Depleted medium with either 5mM 2-Deoxy-D-Glucose or 1!M Antimycin-A was 
added. After 24 hours, the medium was collected for EV isolation. Again, the cells were 
washed twice and the respective EV-Depleted medium was added. This cycle continues 
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until the MSCs reached confluency. This enabled enough EVs to be obtained for each 
bioactivity assay. Once confluent, flasks were then trypsinized and cells were counted to 
develop an EV/cell measure. 
 For MSC spheroid-derived EV bioactivity experiments, MSCs were seeded into 
microcavity 6-well plate inserts at 500 cells per microcavity and incubated for 48 hours to 
allow spheroid formation. After 48 hours, the MSCs were washed twice with 1X PBS and 
2mL EV-Depleted medium was added per well. Glucose-Free, EV-Depleted medium 
with either 5mM 2-Deoxy-D-Glucose or 1!M Antimycin-A was added when a metabolic 
pathway was inhibited. After 24 hours, the medium was collected for EV isolation. 
Again, the cells were washed twice and the respective EV-Depleted medium was added. 
This cycle continued for 12 days to allow for an adequate amount of EVs to be obtained 
for each bioactivity assay. After 12 days, the well plates were trypsinized to determine 
cell viability and count for an EV/spheroid measure.  
2.5 EV Isolation 
EVs were isolated using differential centrifugation and multiple steps. To start, 
the collected medium was centrifuged at 1,000xg for 10 minutes. The supernatant was 
then centrifuged at 2,000xg for 20 minutes, then 10,000xg for 30 minutes. The 
supernatant was then ultracentrifuged at 40,000xg for 2 hours to pellet the EVs. Optiseal 
tubes and a T70i ultracentrifuge rotor (both from Beckman Coulter) were used, and all 
centrifugation was at 4oC. Pelleted EVs were resuspended in 1X PBS and washed twice 
with 1X PBS buffer using Nanosep 300kDa molecular weight cut-off (MWCO) spin 




2.6 BCA Assay 
EVs were resuspended with 1X PBS so total protein could be measured using a 
bicinchroninic acid (BCA) assay kit (G-Biosciences; 786-571). The kit included two 
reagents, Reagent A and Reagent B. This assay requires the preparation of standards, so 
diluted albumin (BSA) standards were created based on a dilution scheme provided by 
Thermo Fisher.26 96-well plates were used: two wells for each standard and two wells for 
each sample to achieve duplicates. Each cuvette contained 200!L of a working reagent, 
which was created using 50 parts of BCA Reagent A and 1 part Reagent B, and 25 !L of 
standard or sample. 96-well plates were then covered from light and incubated at 37oC 
for 30 minutes. After incubation, the absorbance of each well was measured at 562nm 
using a Tecan Spark multimode plate reader provided by the University of Maryland 
Bioworkshop.  
2.7 EV Quantification by NTA 
EV size and concentration was assessed by nanoparticle tracking analysis (NTA) 
using a NanoSight LM10. Samples were manually injected into the sample chamber 
using a syringe, and each sample was measured in triplicate. The camera setting varied 
from 10-14 based on the sample, and the detection threshold was set to 3. An acquisition 
time of 30 seconds was used. NTA analytical software version 2.3 was used to obtain 
data.  
2.8 Extracellular Oxygen Consumption Assay 
 As a measure of cellular metabolism, an extracellular consumption assay (Abcam; 
ab197243) was used. The assay was performed using the protocol provided by the 
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manufacturer. Briefly, BDMSCs were seeded in a 96-well plate in 200!L of culture 
medium. For the initial seeding density experiment, cells were seeded at 100, 1,000, and 
10,000 cell/cm2 and allowed to incubate overnight at 37oC, 5% CO2. For the chemical 
inhibition experiment, cells were seeded at 4x104 cells/well as specified in the provided 
protocol.  The cells incubated overnight, then the medium was changed with 200!L of 
Glucose-Free culture medium, and the cells were allowed to incubate overnight at 37oC, 
5% CO2. After the final incubation period, the medium was replaced with 150!L fresh 
medium, and empty wells (without cells) were filled with 150!L fresh medium to act as 
blanks. 10!L of Extracellular O2 Consumption Reagent was added to each sample well; 
10!L of fresh medium was added to blank wells to maintain consistent volumes. 1!L of 
the test compound (2-Deoxy-D-Glucose or Antimycin-A) was added to the necessary 
wells. Each well was sealed using 100!L of warmed high sensitivity mineral oil, which is 
provided by the manufacturer and is designed to prevent back diffusion of ambient 
oxygen. The plate was then inserted into a Tecan Spark multimode plate reader warmed 
to 37oC, which was provided by the University of Maryland Bioworkshop. A 
measurement was taken at 2 min intervals for 90 min at Ex/Em=380/650nm.  
For data analysis, intensity was plotted against time, each sample intensity value 
corrected with that of the blank. The linear portion of the plot was selected, and linear 
regression was used to determine the slope and correlation coefficient.  
2.9 Gap Closure Assay 
 HUVECs were seeded at 20,000 cells/well into a 96-well plate. The cells were 
allowed to incubate for 24 hours at 37oC, 5% CO2. BioTek’s AutoScratch Wound 
Making Tool (Part Number: 1750012) was used to disrupt the cell monolayer and create a 
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gap. The wells were washed once with 1X PBS to remove any cell debris. The treatments 
were then applied, which are detailed in Table 1. EGM2 was made by adding a 
supplement pack provided by the manufacturer to EBM2, with the purpose being to 
promote HUVEC functionality. An image of the gap was taken immediately (0 hr) using 
a Nikon Eclipse Ti2 inverted microscope. The cells were allowed to incubate for 20 hours 
at 37oC, 5% CO2. An image of the gap was taken after the incubation period (18-20hr). 
ImageJ was used to determine gap closure by tracing the gaps at 0 and 18 or 20 hr to 
determine the gap area. 
Treatment  Medium and Chemicals Used 
Negative Control Endothelial Cell Basal Medium MV 2 
(EBM2) (PromoCell; C-22221) 
Positive Control Endothelial Cell Growth Medium MV 2 
(EGM2)  
BDMSC-EV Treatment EBM2 + 100 ug/mL EVs 
 
EV Treatment derived from 5mM 2-
Deoxy-D-Glucose treated BDMSCs 
EBM2 + 100 ug/mL EVs 
EV Treatment derived from 1uM 
Antimycin-A treated BDMSCs 
EBM2 + 100 ug/mL EVs 
Table 1. Description of the different treatments used in the gap closure assay. There 
are positive and negative controls included. There are three treatments, where 100 
ug/mL of EVs are used for each. The treatments use EVs derived from normal 





 Data are presented as mean±SEM. Differences between groups were analyzed by 
unpaired t-test. To compare data sets of three, one-way ANOVA was used. Notation for 





Chapter 3: Influence of Metabolic Pathways 
Inhibition on MSC EVs 
3.1 Preliminary Experiments and Results 
3.1.1 Confirmation of Initial Seeding Density Effects on MSC EV Production 
Capacity 
 An in-house study was performed to evaluate cell culture parameter effects on 
MSC EVs. This study’s goal is to corroborate the results obtained by Patel, D. et al25, 
who determined that MSC EV production capacity was impacted by initial MSC seeding 
density. The group found that a lower seeding density lead to higher EV production per 
cell.  
 MSCs were seeded in a T-25 at varying densities (100, 1,000, and 10,000 
cells/cm2), and the EVs were collected, isolated, and quantified using NTA. As seen in 
previous studies25, seeding density impacts EV production capacity. The number of EVs 
produced per cell decreased between densities 100 and 10,000 cell/cm2 by ~100 fold 
(p<0.0001) (Figure 6). This finding supports the notion that cell culture parameters, such 
as initial seeding density, have a significant effect on MSC EV production capacity. The 
mechanisms behind this, however, are unknown.  
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Figure 6. Initial seeding density impacts MSC EV production capacity. MSCs were 
seeded at 100, 1,000, and 10,000 cell/cm2. EVs were collected and isolated. 
Quantification was performed using NTA, and the data was normalized to 
determine the number of EVs produced per cell. Three T-25 flasks were used for 
each condition (n=3). Significant difference was calculated using one-way ANOVA 
(****p<0.0001). 
 
3.1.2 Initial Seeding Density Affects MSC Extracellular Oxygen Consumption 
 To explore the potential relationship between cell culture parameter effects and 
metabolism, an extracellular consumption assay was used to determine metabolic 
changes experienced by MSCs are varying seeding densities. As previously mentioned, 
oxygen consumption is an established means of measuring cellular metabolism, as it is a 
direct measure of mitochondrial function. Metabolic activity can drive favorable or 
unfavorable reactions that directly impact the mitochondria, making the two directly 
dependent on either other.  
MSCs were seeded into a 96-well plate at 100, 1,000, and 10,000 cells/cm2, and 
the assay was performed using the protocol provided by the manufacturer. The results of 


























the highest oxygen consumption rate occurring at the lowest seeding density (n=1) 
(Figure 7). No statistical analysis could be performed on this data set. 
These results provide evidence that there could be a direct relationship between 
cell culture parameters and cellular metabolism, which could potentially impact MSC and 
EV function. To explore this relationship, further experimentation will be performed.  
 
Figure 7. Metabolic activity is affected by MSC initial seeding density. MSCs were 
seeded at 100, 1,000, and 10,000 cell/cm2 in a 96-well plate. An extracellular 
consumption assay (Abcam) was performed using the protocol provided by the 
manufacturer. Fluorescent signal was measured using Tecan Spark multimode plate 
reader (n=1).  
 
3.1.3 Successful Chemical Metabolic Pathway Inhibition in MSCs 
 To evaluate the effect of metabolism on MSC and EV activity, glycolysis and 
OXPHOS were inhibited chemically using 2-Deoxy-D-Glucose and Antimycin-A, 
respectively. These chemicals were added to Glucose-Free DMEM, and they were 
introduced to the cells in vitro. The MSCs incubated with the chemicals 24 hours. To 
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assay was performed. In using this assay, a drop of metabolic activity can be seen, and 
proper inhibition can be verified. Untreated MSCs were used as a negative control, where 
regular, glucose-rich medium was used. Two concentrations of each chemical were used 
to test for potential superior dosing.  
 In most cases, metabolism was successfully inhibited using the two chemicals 
(Figure 8). The untreated MSCs (negative control) acted as expected, maintaining high 
metabolic activity compared to those chemically treated. MSCs treated were 1mM 2-
Deoxy-D-Glucose experienced slight metabolic inhibition, but greater inhibition was 
experienced when 5mM 2-Deoxy-D-Glucose was used. MSCs treated with 1!M 
Antimycin-A experience similar metabolic inhibition to those treated with 5!M 
Antimycin-A. No statistical analysis could be performed on this data. 
 Proper metabolic inhibition was achieved when chemically treating the MSCs 
during culture. Based on this data, 5mM 2-Deoxy-D-Glucose will be used when 







Figure 8. MSC metabolism can be inhibited chemically using 2-Deoxy-D-Glucose 
and Antimycin-A. MSCs were seeded in a 96-well plate, and an extracellular 
consumption assay (Abcam) was performed using the protocol provided by the 
manufacturer. Fluorescent signal was measured using Tecan Spark multimode plate 
reader (n=1).  
 
3.2 Results From 2D-Cultured MSCs 
3.2.1 Metabolic Inhibition Does Not Affect 2D-Cultured MSC EV Production  
 MSC EV production capacity was assessed to better understand if metabolic 
pathway inhibition affected MSC behavior when the cells were cultured in a 2D-culture 
system. EV production rate is a critical parameter in biomanufacturing and better 
understanding what affects it is valuable.  MSCs were seeded in a T-25 culture flask at 
100 cells/cm2. The MSCs receiving no treatment were cultured in regular, glucose-rich 
medium, and the chemically-treated MSCs were cultured in Glucose-Free DMEM. EVs 
were collected, isolated, then characterized and quantified using NTA. The average mode 
size of the particles for all experimental groups was within the sizes used to characterize 



















between the experimental groups, indicating physical EV characteristics were unchanged 




















Table 2. Average mode size of the imaged particles from 2D-cutlutred MSCs. The 
average mode size (diameter) was below 200nm for all groups. Based on size, the 
particles imaged can safely be characterized as EVs. Three T-25 flasks were used for 
each condition (n=3).  
 
 
Figure 9. There is no significant difference of the MSC-derived particle’s mode sizes 
when using a 2D-culture system. MSCs were seeded at 100 cell/cm2, and EVs were 
collected and isolated. Size characterization was performed using NTA. Three T-25 
flasks were used for each condition (n=3). No statistical difference found between 







































2D MSC EV Size Comparison
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There was no significant change in MSC EV production capacity when glycolysis 
and OXPHOS were inhibited (n=3) (Figure 10). This indicates there is no relationship 
between metabolism and MSC EV production when a 2D-culture system is used.   
 
Figure 10. There is no significant difference in 2D-cultured MSC EV production 
capacity when glycolysis and OXPHOS are inhibited. MSCs were seeded at 100 
cell/cm2, and EVs were collected and isolated. EV quantification was performed 
using NTA. Three T-25 flasks were used for each condition (n=3). No statistical 
difference found between groups using unpaired t-test (p>0.05). 
 
3.2.2 OXPHOS Inhibition Affects 2D-Cultured MSC EV Bioactivity 
 MSC EV bioactivity was tested to determine the effect of metabolic pathway 
inhibition when the parent MSCs were cultured in a 2D medium. EV bioactivity has a 
direct correlation to their therapeutic efficacy so understanding how it can be impacted is 
critical. MSCs were seeded in a T-175 culture flask at a cell count of 250,000 cells. The 
MSCs receiving no treatment were cultured in regular, glucose-rich medium, and the 







































were collected and isolated. EV concentration was determined using a BCA assay. The 
effect of metabolic pathway inhibition on these EV’s bioactivity was evaluated using an 
in vitro gap closure assay. A 20 hour wait time after the initial scratch was adequate for 
sufficient gap closure. A significant difference in gap closure was seen when comparing 
the EGM2 (positive control) to the EBM2 (negative control) (n=4); this is to be expected, 
































Table 3. Specific mean gap closure values for 2D-cultured MSC EVs. The results 
indicate that basal medium (negative control) has a much lower closure value when 
compared to growth medium (positive control). This is to be expected, showing the 
assay functioned properly. The specific gap closures from all EV treatments can be 
seen as well. Data are representative of four independent experiments (n=4). 
 
When a 100!g/mL dose of EVs were applied, all EV populations increased 
HUVEC gap closure compared to basal medium (Figure 11a). However, a significant 
decrease in gap closure was observed when comparing the EVs isolated from regular 
MSCs (no chemical treatment, no metabolic pathway inhibition) to those isolated from 
OXPHOS-inhibited MSCs (n=4) (Figure 11b). This indicates a potential link between 
MSC EV bioactivity and the OXPHOS metabolic pathway. 
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Figure 11. Impact of metabolic pathway inhibition on MSC EV bioactivity using a 
2D-culture system. (A) HUVECs were stimulated with growth medium (positive 
control), basal medium (negative control), or 100#g/mL EVs isolated from MSCs 
with the indicated treatments. Representative images captured at 0 and 20hr are 
shown. (B) ImageJ analysis comparing of gap closure at 20hr to that at 0hr. The gap 
area is indicated by the white dotted lines. There is a significant decrease in gap 
closure when OXPHOS is inhibited in MSCs, indicating a decrease in EV 
bioactivity. Data are representative of four independent experiments (n=4). 



























































3.3 Results from Microcavity-well Cultured MSCs 
3.3.1 Metabolic Inhibition Affects MSC Spheroid EV Production  
 MSC EV production capacity was also assessed in a microcavity-culture system 
to test consistency between culture platforms. MSCs were seeded in a 6-well microcavity 
plate, with 500 MSCs seeded into each microcavity for proper spheroid formation. The 
MSCs receiving no treatment were cultured in regular, glucose-rich medium, and the 
chemically-treated MSCs were cultured in Glucose-Free DMEM. The MSC-derived EVs 
were collected, isolated, then characterized and quantified using NTA. The average mode 
size of the particles for all experimental groups was within the sizes used to characterize 
EVs (n=3) (Table 4). There was no significant difference of the particle’s mode sizes 
between the experimental groups, indicating physical EV characteristics were unchanged 



















Table 4. Average mode size of the imaged particles from microcavity-well cultured 
MSCs. The average mode size (diameter) was below 200nm for all groups. Based on 
size, the particles imaged can safely be characterized as EVs. Three T-25 flasks were 




Figure 12. There is no significant difference of the MSC-derived particle’s mode 
sizes when using a microcavity-well culture system. MSCs were seeded at 500 
cells/microcavity, and EVs were collected and isolated. Size characterization was 
performed using NTA. Three microcavity-well plates were used for each condition 
(n=3). No statistical difference found between groups using one-way ANOVA 
(p>0.05). 
 
There was a significant decrease in MSC EV production capacity when glycolysis 
and was inhibited, as well as when OXPHOS was inhibited (n=3) (Figure 13). This 
indicates that metabolism impacts and MSC EV production when a microcavity-well 
culture system is used. This result does not reflect those seen when MSCs were cultured 
in a 2D medium (Figure 10), which implies there could be a mechanistic difference in 












































Figure 13. Inhibition of glycolysis and OXPHOS cause a significant decrease in 
MSC EV production capacity when using a microcavity-well culture system. MSCs 
were seeded at 500 cells/microcavity, and EVs were collected and isolated. EV 
quantification was performed using NTA. Three microcavity-well plates were used 
for each condition (n=3). Statistical comparisons determined by unpaired t-test 
(*p<0.1, **p<0.01). 
 
3.3.2 OXPHOS Inhibition Affects Microcavity-Cultured MSC EV Bioactivity 
MSC EV bioactivity was also assessed in a microcavity-culture system to 
determine if there is consistency between culture mediums. MSCs were seeded in a 6-
well microcavity plate, with 500 MSCs seeded into each microcavity for proper spheroid 
formation. The MSCs receiving no treatment were cultured in regular, glucose-rich 
medium, and the chemically-treated MSCs were cultured in Glucose-Free DMEM. EVs 
were collected and isolated, and their concentration was determined using a BCA assay. 
As before, EV bioactivity was evaluated using an in vitro gap closure assay. An 18 hour 
wait time after the initial scratch was adequate for sufficient gap closure. There was 










































which acted as the negative and positive controls, respectively (n=6). This behavior is to 
be expected, indicating the assay is functioning properly.  For specific gap closure values, 

































Table 5. Specific mean gap closure values for microcavity-well cultured MSC EVs. 
The results indicate that basal medium (negative control) has a much lower closure 
value when compared to growth medium (positive control). This is to be expected, 
showing the assay functioned properly. The specific gap closures from all EV 
treatments can be seen. Data are representative of six independent experiments 
(n=6). 
 
When a 100!g/mL dose of EVs were applied, the untreated and 5mM Deoxy-D-
Glucose treated MSC-derived EV populations increased HUVEC gap closure compared 
to basal medium (Figure 14a). A significant decrease in gap closure was observed when 
comparing the EVs isolated from untreated MSCs to those isolated from OXPHOS-
inhibited MSCs (n=6) (Figure 14b). These results implicate a potential relationship 
between OXPHOS and EV bioactivity. The same decrease in EV bioactivity was also 
seen when MSCs were cultured in a 2D-system (Figure 11b), which shows that the 








Figure 14. Impact of metabolic pathway inhibition on MSC EV bioactivity using a 
microcavity-well culture system. (A) HUVECs were stimulated with growth medium 
(positive control), basal medium (negative control), or 100#g/mL EVs isolated from 
MSCs with the indicated treatments. Representative images captured at 0 and 18hr 
are shown. (B) ImageJ analysis comparing of gap closure at 18hr to that at 0hr. The 
gap area is indicated by the white dotted lines. There is a significant decrease in gap 
closure when OXPHOS is inhibited in MSCs, indicating a decrease in EV 
bioactivity. Data are representative of six independent experiments (n=6). Statistical 



























































 Many different factors impact MSC behavior, including as proliferation, 
differentiation, and migration. Various factors can contribute to altering MSC function, 
such as growth factors and extracellular matrix.19 Here, we investigated how cellular 
changes caused by metabolic pathway inhibition may affect the production and 
bioactivity of MSC EVs. Mechanical parameters such as a 2D and 3D culture system 
have been shown to impact MSC activity33,34, and both platforms are commonly used in 
both experimentation and commercial production. Because of this, experiments were 
performed in both 2D and microcavity-well culture to investigate the translation of results 
between the two. Our results suggest a relationship between MSC metabolism, EV 
production capacity, and EV bioactivity.  
3.4.1 Metabolic Inhibition Effects on MSC EV Production  
  The results of this study show that inhibition of both glycolysis and OXPHOS 
significantly decrease MSC EV production capacity when a microcavity-well culture 
system is used, with an inhibition of glycolysis having a greater effect (Figure 13). 
However, in a 2D culture system, there is no significant difference in production capacity 
between untreated and chemically inhibited MSCs (Figure 10). Based on these results, 
the effect of metabolic pathway inhibition on MSCs does not translate between a 2D and 
microcavity-well culture system. This difference in results supports various studies 
detailing the immense change in cellular morphology, physiology, and behavior 
experienced by cells when cultured in a 3D medium.33,34 It is thought that, because of 
this, a 3D-culture system provides more predictive information than that of a 2D-culture 
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system.35,36 This ideology indicates that the decreased EV production capacity resulting 
from the MSC spheroid culture may be more indicative of in vivo phenomena. 
The differing results between culture systems supports previous work suggesting 
cull culture parameters, including mechanical factors, can impact MSC EV production.25 
The use of 3D culture has been shown to effect extracellular signaling in various cell 
types.38 Specifically, it can enhance paracrine signaling and secretions in MSCs39, and 
amongst these paracrine secretions are extracellular vesicles41.  Glycolysis and OXPHOS 
may have an impact on MSC paracrine signaling, which could be intensified when paired 
with the enhanced properties of MSC spheroids. Further study is required to identify the 
mechanistic link between metabolic pathway inhibition and paracrine signaling. In doing 
this, there can be a better understanding as to why different dimensional culture systems 
yield different MSC EV production results when glycolysis and OXPHOS are inhibited.  
3.4.2 Metabolic Inhibition Effects on MSC EV Bioactivity 
  The results of this study show that the inhibition of OXPHOS in MSCs decreases 
EV bioactivity, and the inhibition of glycolysis does not have a statistically significant 
effect. This result is translatable across 2D and microcavity-well culture systems (Figures 
11 and 14). Previous studies have shown that metabolic pathways contribute to both the 
optimization and detriment of MSC function.19 This same effect could be translated to the 
EVs they produce; however, this fact has not previously been proven. These results are a 
good first step in uncovering the potential link between metabolism and EV functionality. 
 This result goes against the initial hypothesis, which predicted that glycolysis 
inhibition would have a more significant effect on MSC EVs than the inhibition of 
OXPHOS. The effect of OXPHOS on MSC EVs could be due to the pathway’s 
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relationship to ATP production. Because OXPHOS operates on the TCA cycle, it 
produces more ATP than glycolysis. Varying levels of interaction between ATP and EVs 
have been shown to modify the EV proteome in other cell types42, and the same may 
occur in MSCs. It is possible that the decreased ATP level associated with OXPHOS 
production altered the common ATP-EV interaction, resulting in a changed EV 
proteome. Further study is required to analyze the potential effects of OXPHOS 
inhibition on the MSC EV proteome and identify it as a potential mechanism behind the 
decrease in EV bioactivity. In doing this, there can be a better understanding of the 
factors that contribute to and impact EV biogenesis. 
3.5 Significance  
 MSC EVs are responsible for a large portion of MSC bioactivity, and they 
contribute to the many regenerative and healing properties experienced by their parent 
cells. MSC EVs have great therapeutic potential, which has been evidenced in various 
studies and disease models.4-5 However, the lack of knowledge behind the culture 
parameters and mechanisms that drive MSC EV biogenesis and bioactivity acts as a 
barrier to their widespread clinical use. Metabolism has been shown to greatly contribute 
to MSC behavior and functionality19-20, and it is hypothesized to be the mechanism 
behind the many variations in MSC EV production and bioactivity experienced in cell 
culture.25 Here, we take the first steps toward revealing a mechanistic relationship 
between metabolism and MSC EVs. By better understanding how the two are related, 
there can be a greater insight into the factors that drive MSC EV production and 
bioactivity, improving the knowledge behind the mechanisms that drive EV biogenesis. 
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A greater understanding increases the possibility for realistic clinical translation and 
application of EVs.  
 When considering the results obtained when using a microcavity-based culture 
system, the inhibition of glycolysis and OXHPOS significantly decreases MSC EV 
production capacity. This result is valuable, as it reveals a previously unknown potential 
mechanism driving EV biogenesis in MSCs. It also allows for the possibility to optimize 
MSC EV production. Once EVs are cleared for clinical use, glycolysis and OXPHOS can 
be utilized as a vehicle to enhance MSC EV production in the biomanufacturing process. 
Future studies can explore the potential for metabolic pathway promotion, rather than 
inhibition, to see if MSC EV production is increased. If this is the case, this mechanism 
can be used to optimize the biomanufacturing and production of MSC EVs, which is a 
crucial component to the realistic use of EVs as a therapeutic.  
 While the inhibition of glycolysis seems to have no effect, the inhibition of 
OXPHOS significantly decreases MSC EV bioactivity. This result reveals that not only 
can metabolic pathways play a role in MSC EV production capacity, but it may also be a 
mechanism impacting EV behavior and functionality. This is a fact that can, again, be 
used to optimize MSC EV biomanufacturing. Future studies can observe the effects of 
metabolic pathway promotion on EVs, and it can be determined if EV bioactivity can 
potentially be improved. If this is observed, it is a mechanism that has incredible value. 
The therapeutic potential of MSC EVs can be enhanced, and the regenerative effects seen 
in previous studies4-5 can be improved. The manipulation of MSC metabolic pathways in 
vitro can positively impact the efficacy of MSC EV use in various medical treatments.   
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Chapter 4: Conclusions 
4.1 Summary 
 MSC EVs are responsible for a large amount of MSC function and bioactivity. 
These EVs have great therapeutic potential that has been proven in many different 
applications, such as reduction of myocardial injury and wound healing.4 EV treatment 
has potential advantages over MSC transplantation in that they are considered more 
stable, have a well-defined clearance pathway, and are unable to proliferate or 
differentiate. Despite the rising interest and advantages of MSC EVs, there are many 
barriers to realistic clinical use, the most prevalent of which being lack of knowledge 
detailing the driving forces of their biogenesis. It is unknown how different cell culture 
parameters impact MSC EVs on a mechanistic level, and this leads to great variation in 
both MSC EV production and bioactivity across different culture systems. It has been 
previously hypothesized that cellular metabolism is the mechanism behind the variations 
in MSC EVs experienced between cell cultures25, but this has never been proven.  
 The enclosed findings provide insights into the effects of cellular metabolism on 
MSC EV production capacity and bioactivity. These results provide a greater 
understanding of metabolism as a mechanistic link between cell culture effects of MSCs 
and the EVs they produce. The results also provide potential ways to better improve 
biomanufacturing processes in the future, which is critical to the efficient clinical 
translation of EVs. Key findings of this study include: 
• Metabolic pathway inhibition may impact MSC EV production. The 
inhibition of glycolysis and OXPHOS did not significantly decrease MSC EV 
production when a 2D-culture system was used. However, when using a 
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microcavity-well culture system, the inhibition of glycolysis and OXPHOS did 
significantly decrease MSC EV production capacity. The lack of translation 
between culture systems can be attributed to the changes in behavior experienced 
by MSC spheroids. Glycolysis and OXPHOS may have an impact on MSC 
paracrine signaling, which could be enhanced with the improved properties 
associated with MSC spheroids. Further study is needed to identify if there is truly 
a mechanistic relationship between metabolism and MSC EV production capacity.  
• Metabolic pathway inhibition significantly decreases MSC EV bioactivity. In 
both a 2D and microcavity-well culture system, the inhibition of OXPHOS 
significantly decreases MSC EV bioactivity. The inhibition of glycolysis does not 
have a statistically significant effect. These results defy the initial hypothesis that 
glycolysis would have a more significant effect than OXPHOS. Further studies 
are required to better understand this mechanistic relationship and the details 
behind it.   
4.2 Future Directions  
 This work was completed to better understand what mechanisms effect MSC EV 
biogenesis. More specifically, we investigated if metabolism plays a significant role in 
MSC EV production capacity and bioactivity. Conclusions from this research indicate 
that this is very much a possibility. The next steps will be to further study the relationship 
between metabolic pathways and MSC EVs. In doing this, a greater understanding of 
MSC EV biogenesis can be gained, and there can be improved efficiency in potential 
strategies for MSC EV biomanufacturing, making the clinical translation of EVs more 
realistic.  
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 To determine if metabolism truly impacts MSC EV production capacity, further 
study is necessary. Because of the inconsistency in results between 2D and microcavity-
well culture systems, the results received here are indicative of a potential relationship, 
but they are not conclusive. The experiments could be repeated using a different 
quantitative method than NTA to determine EV count. Tetraspanin CD63 is a common 
biomarker associated with EVs, and it has been deemed by the International Society of 
Extracellular Vesicles as an acceptable protein to characterize EVs by.43 Therefore, a 
CD63 ELISA can be performed to quantify the MSC EVs. In using this method, more 
decisive results may be achieved.  
 To better understand the role of metabolism in MSC EV bioactivity, further study 
is needed. The results obtained here indicate that the inhibition of OXPHOS significantly 
decreases MSC EV bioactivity. Although this relationship is established, the mechanism 
behind it is still unknown. To potentially gain insight into this mechanism, future studies 
can investigate if changes in MSC EV proteome are experienced during OXPHOS 
inhibition. OXPHOS is responsible for a large amount of ATP production. Previous 
studies have shown that interactions between ATP and EVs can modify the EV proteome. 
This may be the mechanism behind the changes in EV bioactivity seen here.  
 It would be beneficial to perform the experiments described with metabolism 
promoters instead of inhibitors. Whether it by the addition of nutrients (e.g. glucose) or 
metabolites (e.g. lactate), the aim would be to increase metabolic activity. Here, MSC EV 
production and bioactivity would be tested in the interest of seeing if these parameters are 
increased when metabolism is enhanced. If this is the case, metabolism is a cellular 
parameter that can be utilized in MSC EV biomanufacturing to make processes more 
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fruitful and efficient. By providing a means to improve MSC EV yield during 
biomanufacturing, as well as enhance EVs therapeutic potential by improving its 
bioactivity, the clinical translation of EVs is significantly more achievable.  
 If future experiments are performed to better understand the effects of metabolism 
on MSCs and their EVs, it may be worthwhile to explore a different culture system than 
the microcavity-well plate. Although the microcavity-well plate was able to successfully 
form MSC spheroids (Figure 5), it seems improved cell-cell interactions is the only 
altered cell culture condition. Aside from this, the culture system is like that of a 
standard, 2D 6-well plate. Other multi-dimensional culture systems allow for more 
realistic cell conditions, such as complex surface shapes, altered mechanical properties, 
and the application of shear. The creation of a more realistic cell culture environment 
could more significantly impact cell behavior, which could translate to the EVs they 
produce. For example, in a study using a scaffold-perfusion bioreactor system to culture 
endothelial cells, both EV production and bioactivity was enhanced compared that of a 
2D-culture system44.  To achieve more realistic cell culture conditions and changes in 
MSC behavior, any future studies should consider using a bioreactor system instead of 
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